VRTX - Company ID 0000875320
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported net income of $3.95B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $3.95B | +838.1% |
| FY 2024 | -$535.60M | -114.8% |
| FY 2023 | $3.62B | +9.0% |
| FY 2022 | $3.32B | +41.8% |
| FY 2021 | $2.34B | -13.6% |
| FY 2020 | $2.71B | +130.4% |
| FY 2019 | $1.18B | -43.9% |
| FY 2018 | $2.10B | +695.8% |
| FY 2017 |
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported net income of $3.95B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, VERTEX PHARMACEUTICALS INC / MA's net income grew from $29.57M to $3.95B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $263.48M |
| +335.1% |
| FY 2016 | -$112.05M | +79.9% |
| FY 2015 | -$556.33M | +24.7% |
| FY 2014 | -$738.55M | -66.0% |
| FY 2013 | -$445.03M | -315.8% |
| FY 2012 | -$107.03M | -461.9% |
| FY 2011 | $29.57M | - |